Drugs / NELUTROCTIV
NELUTROCTIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05662215 | Dec 2022 → Aug 2023 | — | Cytokinetics | Terminated | Met primary Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-29 | Cytokinetics | Results Cytokinetics Announces Preclinical Data Relating to CK-3828136 Presented at the 2021 Medicinal Chemistry Gordon Research Conference cytokinetics.com ↗
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data relating to the discovery and optimization of CK-3828136 (CK-136) were presented at the 2021 Medicinal Chemistry Gordon Research Conference in West Dover, VT. |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NELUTROCTIV | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314433 ↗ |
| Known as | AMG 594 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314433 ↗ |
| Known as | CK-136 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314433 ↗ |
| Known as | CK-3828136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05662215 ↗ |
| Modality | Small molecule | — CHEMBL5314433 ↗ |